DACH1

Across TCGA pan-cancer cohorts, DACH1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DACH1 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DACH1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DACH1 expression acts as an unfavorable survival marker, although some lineages such as SCLC and SKCM show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where DACH1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.150	0.560	<.001	23	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	IV	0.079	0.480	<.001	6	view →
SCLC	OS	Median	IV	0.719	0.167	.035	3	view →
SKCM	OS	Median	II,III,IV	0.919	0.717	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DACH1–LIHC (DFS)

Open the LIHC breakdown →